15.02.2017 • NewsElaine BurridgeIPOAlzChem

Germany’s AlzChem Postpones IPO

(c) Alzchem
(c) Alzchem

German chemical producer AlzChem has decided to postpone its planned initial public offering (ipo), blaming political issues for causing persistent uncertainty for new investments. Trading of AlzChem’s shares was originally planned to start on the Frankfurt Stock Exchange on Feb. 10.

The Bavarian company, which manufactures products based on the nitrogen-carbon-nitrogen (NCN) chain, was planning to raise between €40 million and €50 million from the IPO, with most of the proceeds to be invested in a new specialty chemical plant at its base in Trostberg. AlzChem said it will now make use of alternative financing possibilities to fund further growth and will re-evaluate an IPO at a later date.

Formerly part of Evonik before being sold to an investment fund in 2009, AlzChem has a leading position in selected niche markets, including feed additives and food supplements. It has four production sites in Germany, a carbide plant in Sweden, as well as subsidiaries in the US and China, employing nearly 1,500 people altogether.

 

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.